Platelets from flowing blood attach to the inflammatory chemokine CXCL16 expressed in the endothelium of the human vessel wall

Summary

Endothelial chemokine CXC motif ligand 16 (CXCL16) expression is associated with atherosclerosis, while platelets, particularly those attaching to atherosclerotic plaque, contribute to all stages of athero-sclerotic disease. This investigation was designed to examine the role of CXCL16 in capturing platelets from flowing blood. CXCL16 was expressed in human atherosclerotic plaques, and lesion severity in human carotid endarterectomy specimens was positively correlated with CXCL16 levels. CXCL16 expression in plaques was co-localised with platelets deposited to the endothelium. Immobilised CXCL16 promoted CXCR6-dependent platelet adhesion to the human vessel wall, endothelial cells and von Willebrand factor during physiologic flow. At low shear, immobilised CXCL16 captured platelets from flowing blood. It also induced irreversible platelet aggregation and a rise in intra-platelet calcium levels. These results demonstrate that endothelial CXCL16’s action on platelets is not only limited to platelet activation, but that immobilised CXCL16 also acts as a potent novel platelet adhesion ligand, inducing platelet adhesion to the human vessel wall.

Keywords

Adhesion - adhesion receptors - chemokines - platelets - vascular inflammation

• References

• 1 Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161-165.
• 2 Adler MW, Rogers TJ. Are chemokines the third major system in the brain?. J Leukoc Biol 2005; 78: 1204-1209.
• 3 Hundhausen C, Schulte A, Schulz B. et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J Immunol 2007; 178: 8064-8072.
• 4 Ludwig A, Weber C. Transmembrane chemokines: versatile ’special agents’ in vascular inflammation. Thromb Haemost 2007; 97: 694-703.
• 5 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
• 6 Matloubian M, David A, Engel S. et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000; 01: 298-304.
• 7 Abel S, Hundhausen C, Mentlein R. et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172: 6362-6372.
• 8 Gough PJ, Garton KJ, Wille PT. et al. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004; 172: 3678-3685.
• 9 Schulz C, Schafer A, Stolla M. et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764-773.
• 10 Schafer A, Schulz C, Eigenthaler M. et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412.
• 11 Meyer dos Santos S, Klinkhardt U, Scholich K. et al. The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glyco-protein Ib. Blood 2011; 117: 4999-5008.
• 12 Hofnagel O, Engel T, Severs NJ. et al. SR-PSOX at sites predisposed to athero-sclerotic lesion formation mediates monocyte-endothelial cell adhesion. Atherosclerosis 2011; 217: 371-378.
• 13 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
• 14 Meyer Dos Santos S, Klinkhardt U, Schneppenheim R. et al. Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions. Platelets 2010; 21: 60-66.
• 15 Meyer Dos Santos S, Kuczka K, Picard-Willems B. et al. The integrin antagonist, cilengitide, is a weak inhibitor of alphaIIbbeta3 mediated platelet activation and inhibits platelet adhesion under flow. Platelets 2015; 26: 59-66.
• 16 Andrews S, Gilley J, Coleman MP. Difference Tracker: ImageJ plugins for fully automated analysis of multiple axonal transport parameters. J Neurosci Methods 2010; 193: 281-287.
• 17 Methia N, Andre P, Denis CV. et al. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98: 1424-1428.
• 18 Theilmeier G, Michiels C, Spaepen E. et al. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99: 4486-4493.
• 19 van Galen KP, Tuinenburg A, Smeets EM. et al. Von Willebrand factor deficiency and atherosclerosis. Blood Rev 2012; 26: 189-196.
• 20 Seizer P, Stellos K, Selhorst G. et al. CXCL16 is a novel scavenger receptor on platelets and is associated with acute coronary syndrome. Thromb Haemost 2011; 105: 1112-1114.
• 21 Raab M, Daxecker H, Markovic S. et al. Variation of adhesion molecule expression on human umbilical vein endothelial cells upon multiple cytokine application. Clin Chim Acta 2002; 321: 11-16.
• 22 Yago T, Lou J, Wu T. et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. J Clin Invest 2008; 118: 3195-3207.
• 23 Berndt MC, Metharom P, Andrews RK. Primary haemostasis: newer insights. Haemophilia 2014; 20 (Suppl. 04) 15-22.
• 24 Minami M, Kume N, Shimaoka T. et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscl Thromb Vasc Biol 2001; 21: 1796-1800.
• 25 Wuttge DM, Zhou X, Sheikine Y. et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in athero-sclerotic lesions. Arterioscl Thromb Vasc Biol 2004; 24: 750-755.
• 26 Yi GW, Zeng QT, Mao XB. et al. Overexpression of CXCL16 promotes a vulnerable plaque phenotype in Apolipoprotein E-Knockout Mice. Cytokine 2011; 53: 320-326.
• 27 Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006; 114: 583-590.
• 28 Sheikine Y, Sirsjo A. CXCL16/SR-PSOX--a friend or a foe in atherosclerosis?. Atherosclerosis 2008; 197: 487-495.
• 29 Lehrke M, Millington SC, Lefterova M. et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007; 49: 442-449.
• 30 Yamauchi R, Tanaka M, Kume N. et al. Upregulation of SR-PSOX/CXCL16 and recruitment of CD8+ T cells in cardiac valves during inflammatory valvular heart disease. Arterioscl Thromb Vasc Biol 2004; 24: 282-287.
• 31 Smith C, Halvorsen B, Otterdal K. et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res 2008; 79: 195-203.
• 32 Dahl CP, Husberg C, Gullestad L. et al. Increased production of CXCL16 in experimental and clinical heart failure: a possible role in extracellular matrix remodeling. Circ Heart Fail 2009; 02: 624-632.
• 33 Jansson AM, Aukrust P, Ueland T. et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009; 119: 3181-3188.
• 34 Ueland T, Smedbakken LM, Hallen J. et al. Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis 2012; 220: 244-249.
• 35 Wang KD, Liu ZZ, Wang RM. et al. Chemokine CXC Ligand 16 serum concentration but not A181V genotype is associated with atherosclerotic stroke. Clin Chim Acta 2010; 411: 1447-1451.
• 36 Yang T, Li ZN, Chen G. et al. Increased levels of plasma CXC-Chemokine Ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension. Heart Lung 2014; 43: 322-327.
• 37 Sun Y, Chang Z, Zhang S. Increased serum CXCL16 level is a marker for acute coronary syndromes. Arch Med Res 2008; 39: 332-337.
• 38 Mitsuoka H, Toyohara M, Kume N. et al. Circulating soluble SR-PSOX/CXCL16 as a biomarker for acute coronary syndrome -comparison with high-sensitivity C-reactive protein. J Atheroscl Thromb 2009; 16: 586-593.
• 39 Tan K, Lu S, Chen Y. et al. CXC chemokine ligand 16 as a prognostic marker in patients with intermediate coronary artery lesions: a 2-year follow-up study. Tohoku J Exp Med 2011; 223: 277-283.
• 40 Ma A, Pan X, Xing Y. et al. Elevation of serum CXCL16 level correlates well with atherosclerotic ischemic stroke. Arch Med Sci 2014; 10: 47-52.
• 41 Lv Y, Hou X, Ti Y. et al. Associations of CXCL16/CXCR6 with carotid atherosclerosis in patients with metabolic syndrome. Clin Nutr 2013; 32: 849-854.
• 42 Zhao G, Wang S, Wang Z. et al. CXCR6 deficiency ameliorated myocardial ischemia/reperfusion injury by inhibiting infiltration of monocytes and IFN-gamma-dependent autophagy. Int J Cardiol 2013; 168: 853-862.
• 43 Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis 2014; 236: 108-115.
• 44 Kim CH, Kunkel EJ, Boisvert J. et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001; 107: 595-601.
• 45 Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 2002; 100: 11-16.
• 46 Nakayama T, Hieshima K, Izawa D. et al. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003; 170: 1136-1140.
• 47 Borst O, Munzer P, Gatidis S. et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/akt signaling. Circulation Res 2012; 111: 1297-1307.
• 48 Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207: 541-543.
• 49 Flamm MH, Diamond SL. Multiscale systems biology and physics of thrombosis under flow. Ann Biomed Engin 2012; 40: 2355-2364.
• 50 Petit SJ, Chayen NE, Pease JE. Site-directed mutagenesis of the chemokine receptor CXCR6 suggests a novel paradigm for interactions with the ligand CXCL16. Eur J Immunol 2008; 38: 2337-2350.